Skip to main content
Clinical Trials/NCT05624242
NCT05624242
Not yet recruiting
Not Applicable

Assessment of Right Ventricular Function by Cardiac Magnetic Resonance Imaging in Patients With Pulmonary Arterial Hypertension (IRMA)

Central Hospital, Nancy, France0 sites130 target enrollmentFebruary 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pulmonary Arterial Hypertension
Sponsor
Central Hospital, Nancy, France
Enrollment
130
Primary Endpoint
Transplantation-free survival
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

Pulmonary hypertension (PH) is a pathophysiological condition defined by an increase in pulmonary arterial pressure above 20mmHg, which encompasses many very dissimilar conditions. Right ventricular function is the major determinant of survival in these patients. Currently, right ventricular function is estimated by trans-thoracic echocardiography via the measurement of standardised parameters. However, cardiac magnetic resonance imaging is now the reference technique for non-invasive quantification of volumes, mass, function of the right ventricle but can also be useful for the consideration of the pulmonary circulation. Thus, indices of function can be extracted and it plays an increasing role in the prognostic evaluation of the right heart function at diagnosis and at re-evaluation under treatment of pulmonary arterial hypertension. This work will initially focus on the assessment of right ventricular myocardial work by echocardiography and cardiac magnetic resonance imaging in comparison with invasive haemodynamic data.

Registry
clinicaltrials.gov
Start Date
February 1, 2023
End Date
December 1, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Central Hospital, Nancy, France
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient with pulmonary arterial hypertension (group 1)
  • Patient with cardiac MRI, echocardiography and right heart catheterisation within 1 month of each other

Exclusion Criteria

  • Patient with features of venous/capillary involvement
  • Pulmonary arterial hypertension associated with with congenital heart disease
  • Patient's decline to participate in the study

Outcomes

Primary Outcomes

Transplantation-free survival

Time Frame: 12 months

Similar Trials